Jagsonpal Pharmaceuticals Ltd Share Price

Pharmaceuticals - Indian - Bulk Drugs & Formln M/SNSE
₹209.27
-1.15-0.55% (1D)
As on 20 Nov 2026 at 15:59
As of 20 Nov 2026 at 15:59, Jagsonpal Pharmaceuticals Ltd is trading at ₹209.27. The 52-week range stands at ₹155.00–₹264.50, with a market cap of ₹1.37 thousand crore. At a P/E of 29.03 and a dividend yield of 1.95%, it is a small-cap stock in the Pharmaceuticals sector.

JAGSNPHARM Price Chart

Market Cap
₹1.37K Cr
PE Ratio
29.03
ROCE
24.59%

Jagsonpal Pharmaceuticals Ltd Performance

Jagsonpal Pharmaceuticals Ltd Fundamentals

Know More
Market Cap₹1.37K Cr
ROE18.66%
P/E Ratio (TTM)29.03
EPS (TTM)₹7.15
P/B Ratio5.62
Dividend Yield1.95%
Industry P/E91.72
Book Value₹36.91
Debt to Equity0.03
Face Value₹2

Jagsonpal Pharmaceuticals Ltd Shareholding Pattern

Know More
Promoter68.8%
Foreign Institutions2.1%
Mutual Funds0%
Domestic Institutions0%
Public29%

Jagsonpal Pharmaceuticals Ltd Financial Statements

Know More
No data for this view.

Jagsonpal Pharmaceuticals Ltd Peer Comparison

Know More
StocksLTP(₹)Market Cap(Cr)52 Week Low-High(₹)
Sun Pharmaceutical Industries Ltd
₹1,885.10
-14.90(-0.78%)
4,52,298.61,583.7 - 2,046.9
Torrent Pharmaceuticals Ltd
₹4,698.80
87.80(+1.90%)
1,78,727.33,672.3 - 5,250.0
Dr Reddys Laboratories Ltd
₹1,390.50
-10.40(-0.74%)
1,16,144.51,101.0 - 1,414.9
Cipla Ltd
₹1,414.95
-3.55(-0.25%)
1,14,312.11,165.7 - 1,539.7
Lupin Ltd
₹2,010.00
11.20(+0.56%)
91,915.91,892.9 - 2,529.5

About Jagsonpal Pharmaceuticals

Promoted by Rajpal Singh Kochhar in August, 1978, Jagsonpal Pharmaceuticals Limited is engaged in the manufacture and marketing bulk drugs and pharmaceuticals at its plant at Faridabad in Haryana. The Company has adopted the strategy of clubbing all its products in seven groups for effective marketing and reducing costs. Simultaneously, it has geared up to set up an ultra modern multi-purpose basic drugs and formulation plant through its subsidiary, Jagsonpal Exports India Pvt Ltd. The company has a strategic alliance with Fidia Spa, Italy; and B Spofola, Czechoslovakia; to manufacture sophisticated drugs in India. It has tied up with another Israel-based company, Makhteshim Chemical Works, for acquiring the marketing rights of an anti-oxidant product. In 1994, the company has also promoted Aresco Financial Services, a new financial company. The Company's R&D activities have resulted in manufacturing process upgradation, improving packaging, and cost containment. It's R&D activities are geared towards development of new product technologies which can be commercialised in future. It has tied up with Lycored Natural Products Industries (LNP) of Israel, to launch a completely natural Lycopene bioactive product, Lycored, in India and SouthEast Asia. In the fiscal 2001, the company's sales grew by 15% to Rs 136.52 crore and the profit at the net level was up 8% to Rs 10.15 crore. This was achieved against heavy odds, such as, sluggish market trends, lower growth rate of the industry and severe competition from drug majors. However the company has introduced various measures to counter the above factors so as to achieve continued growth and opportunity. The new manufacturing facility at Pantnagar, Uttarakhand started production in April 2009. The Company launched two brands, Divatrone and ProRetro in the market segment, Dydrogesterone, which was earlier dominated by a global pharma Company in August, 2021. On June 27, 2022, Infinity Holdings, an India-focused investment group acquired control over the Company consequent to acquisition of 43.73% of equity capital and became Promoters of the Company. The Company identified several products as part of new launches such as Indocap Gel, Lycored Plus, MemUp, Queezy ER to enhance healthcare professionals' confidence and improve patient outcomes in 2023-24. It acquired the India and Bhutan business of Yash Pharma in June, 2024. The Company acquired 85% equity stake in Aequitas Healthcare in July 2026.

Parent Organisation—
Founded1978
Managing DirectorManish Gupta
NSE SymbolJAGSNPHARM

Jagsonpal Pharmaceuticals Ltd Resistance and Support levels

R3217.37R2214.52R1212.77S1207.08S2205.33S3202.49209.27

Jagsonpal Pharmaceuticals Ltd Technicals

Current Price
₹209.27 ₹1.15 (-0.55%)
Bearish
12
Bullish
0
  • 20 Day3.4%
  • 50 Day5.6%
  • 100 Day5.8%
  • 200 Day4.3%

Jagsonpal Pharmaceuticals Ltd Latest News

View More
21 OCT 2026 | Wednesday
Jagsonpal Pharmaceuticals to review quarterly results at a board meeting on October 28
09 OCT 2026 | Friday
Jagsonpal Pharmaceuticals submits certificate to BSE and NSE regarding share transfer
30 SEPT 2026 | Wednesday
Jagsonpal Pharmaceuticals increased share capital by allotting equity shares to eligible employees
25 SEPT 2026 | Friday
Jagsonpal Pharmaceuticals closes trading window ahead of financial results declaration
23 SEPT 2026 | Wednesday
Jagsonpal Pharmaceuticals acquires Group Pharmaceuticals’ Wellness Portfolio for Rs 23.7 crores
24 AUG 2026 | Monday
Jagsonpal Pharmaceuticals allotted equity shares under its 2022 Employee Stock Option Plan
29 JUL 2026 | Wednesday
Jagsonpal Pharmaceuticals shareholders to vote on a 200% dividend at AGM
29 JUL 2026 | Wednesday
Jagsonpal Pharmaceuticals approves grant of 120,000 employee stock options under its 2022 plan
29 JUL 2026 | Wednesday
Jagsonpal Pharmaceuticals appoints Balmukund Keshav and Sanjay Singhal to senior management roles
23 JUL 2026 | Thursday
Jagsonpal Pharmaceuticals schedules board meeting

2026

Quarterly ResultRelease dateCheck Latest financial
Quarterly ResultRelease dateCheck Latest financial
Quarterly ResultRelease dateCheck Latest financial
Board MeetingAnnounced
Quarterly ResultRelease dateCheck Latest financial

Frequently asked questions

The share price of Jagsonpal Pharmaceuticals Ltd is ₹209.27 as of 20 Nov 2026 at 15:59.

Not sure where to start?

Book a free 30-minute consultation with our investment experts today!

Invest Now